Background {#Sec1}
==========

Drug-related problems are an important cause of morbidity and mortality and a significant burden on healthcare resources. A high rate of adverse drug reactions (ADRs) has been demonstrated in hospitalized patients \[[@CR1]--[@CR4]\], potentially leading to death. As patients with severe or acute unexpected symptoms frequently present to emergency departments (EDs), some epidemiological studies of ADRs have been successfully conducted in this setting, showing that approximately 10--17 % of ED visits were related to an ADR \[[@CR5], [@CR6]\].

The definition of self-medication is still debated. According to the National Library of Medicines' MeSH (Medical Subject Headings) database, self-medication refers to self-administration of a medication not prescribed by a physician, or in a manner not directed by a physician. Furthermore, the WHO defines self-medication as the selection and use of medicines by individuals to treat self-recognized illnesses or symptoms \[[@CR7]\], and cites self-medication as a common problem leading to incorrect use of medicine \[[@CR8]\]. Therefore, a patient-based approach of self-medication should include all modalities of self-use of drugs, whether previously prescribed or not. This study was based on such a patient-based approach.

Despite numerous studies on ADRs, there are no available data informing us about the rate of ADRs directly related to self-medication (ADR-SM). As such, the risk related to current self-medication behaviours is under-investigated. In the ED-specific context, previously published studies \[[@CR5], [@CR6]\] have not focused on the link between self-medication and ADRs. No data on the rate and severity of ADRs related to self-medication in this setting are available.

To determine the prevalence ratio and severity of ADR-SM in the ED population, we designed a multicentre, ED-based, cross-sectional survey in 11 French hospitals. We also attempted to identify the characteristics of ED patients and their drugs associated with ADRs and ADR-SM.

Methods {#Sec2}
=======

Study Design {#Sec3}
------------

During the 8-week period from 1 March until 20 April 2010, a prospective, cross-sectional, observational study was conducted in the ED of 11 French academic hospitals distributed throughout the country.

Definition of self-medication in the study protocol:To take drugs without relevant prescription (sold without prescription, rest of an ancient prescription or prescribed for another person)A self-modification of treatmentA self-discontinuation of treatment

Approvals {#Sec4}
---------

The study protocol and patient informed consent procedures were approved by the Ethics Committee (St. Etienne CHU on 10 February 2008), and the Committee on Information in Health Research (CCTIRS/CNIL), according to French rules in clinical research.

Sampling and Randomization {#Sec5}
--------------------------

A high volume of visits in participating EDs precluded uninterrupted prospective screening for inclusion throughout the study period. Additionally, as rates of hourly ED visits varied markedly within each day and from one day to another, we defined 13 time slots a priori covering the 24-h day as follows: 10 time slots of 1 h (from 10:00 am to 2:00 pm and from 5:00 pm to 11:00 pm), one time slot of 8 hours (from 11:00 pm to 7:00 am) and two time slots of 3 h (from 7:00 am to 10:00 am and from 2:00 pm to 5:00 pm). Subsequently, we randomly allocated these 13 predefined time slots throughout the 8 weeks of the study period for each participating ED. Randomization was done with computer-generated codes prior to the study enrolment period by our clinical research unit, which was not involved in data collection or patient care. Allocations were disclosed to research staff in every participating ED just prior to the study enrolment period. This method was designed to limit the potential for sampling bias. Additionally, patient demographics (age, gender and acute severity triage score) \[[@CR9]\] were collected from administrative data of each participating centre over the same 8-week enrolment period. These data were compared with the overall study population to verify the representativeness of the ED population studied.

Patient Enrolment {#Sec6}
-----------------

All adult patients presenting to participating EDs during one of the predefined time slots were eligible for study enrolment. On entry, they were informed with a specific form about the study and the opportunity to participate. Medical or pharmacy students (hereafter designated as research staff) in every participating ED were specifically trained to screen candidates for study enrolment, using standardized screening forms. Consenting patients were subsequently included in the absence of exclusion criteria.

Exclusion Criteria {#Sec7}
------------------

The following were precluded because we aimed to describe self-medication behaviour and unintentional related ADRs: (i) patients unable to participate because of cognitive impairment, neuropsychiatric disorders, language barriers or having presented with an unstable medical illness in the absence of a near relative who could answer for them; (ii) patients presenting for attempting suicide; and (iii) declining study participate (a written information form was submitted to patients and/or their relatives at the time of their admission to the ED). In each instance, the reason for exclusion was systematically recorded.

Variables and Data Collection {#Sec8}
-----------------------------

Self-medication behaviours were explored by a standardized questionnaire that had been previously built, implemented and tested in one centre \[[@CR10]\] (see electronic supplementary material). This questionnaire is divided into two parts. The first part consists of a set of 20 closed-ended questions exploring all indications and dimensions of self-medication. The second part collects the characteristics of each medication cited by the patient during the first part (dosage, time between last dose and the ED visit, origin).

The method of data collection during the ED evaluation was then tested in three voluntary centres, which included standardized interviews of patients and/or their surrogates, as well as review of the medical record (i.e. physician notes and orders, laboratory reports, nursing notes, discharge instructions and ongoing prescriptions). Special attention was paid to all medications taken within 2 weeks prior to patient enrolment, including prescribed and non-prescribed drugs. All data were entered using online electronic case report forms (e-CRF), which allowed for real-time assessment of data completeness and patient follow-up. Data collection was performed by the local research staff, which was monitored by a clinical research pharmacist and supervised by the investigators.

Adverse Drug Reaction (ADR) Identification Process {#Sec9}
--------------------------------------------------

The primary outcome was the diagnosis of ADR-SM and the identification of clinical and biological findings related to the effect of the drug(s). The investigators reviewed all cases to identify ADRs in each study centre, based on VIDAL dictionary (French book summarizing the characteristics of all medications, including pharmacology, adverse effects and drug-drug interactions). The local investigators were helped by the Naranjo scale \[[@CR11]\] for drug causality assessment. Nevertheless, whatever could be the result of this score, they were asked to transmit all clinically relevant cases. The severity of the ADRs was assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) \[[@CR12]\], as (A) spontaneous regression; (B) regression after symptomatic treatment; (C) hospitalization with no life-threat; (D) life-threatening risk; and (E) death. The diagnosis of ADR and the drug causality assessment were then documented in the e-CRF. If necessary, notification of cases of drug toxicity was provided to the pharmacovigilance regional centre at the discretion of the local investigator.

All contentious issues transmitted by local investigators, every ADR-SM case (whether contentious or not), and some randomly assigned files were reviewed by an expert committee comprised of therapeutics professors, clinical pharmacists and emergency physicians, whose meetings and minutes were managed by the clinical research pharmacist. Furthermore, the entire database was scrutinized by the clinical research pharmacist in order to detect each case potentially related to an ADR; the expert committee was asked to assess such cases and to confirm drug causality (in order to validate the main outcome). Every local investigator was also asked to verify each subject file and to transmit all useful information regarding the possibility of an ADR to the expert committee. This committee was finally able to resolve each contentious case, and to validate the entire database. Last, the expert committee determined, for each ADR-SM case, the type of self-medication leading to the adverse event: self-modification of a prescribed treatment, discontinuation of treatment, non-prescribed drugs, or a drug interaction with non-prescribed drugs (i.e. self-prescription).

Grouping of Data {#Sec10}
----------------

The diagnosis of the chief complaint and that of the ADR were first encoded to the International Classification of Diseases, 10th revision (ICD-10). To further improve grouping, data were re-coded using a standardized classification designed by the Société Française de Médecine d'Urgence (SFMU: French Society of Emergency Medicine) \[[@CR13]\]. All drugs cited by patients, whether prescribed or not, were encoded to the Anatomical Therapeutic Chemical (ATC) classification system \[[@CR14]\]. Medications not covered by the ATC were encoded as 'Z' (herbal medicines, vitamins, food supplements, calcium, magnesium, diosmine, anti-nausea or anti-diarrhoea pills, some medicines for constipation, balms and topical emollients, topical medicines for common cold, some anti-tussive syrups, omega 3 ...).

Statistical Analysis of Data {#Sec11}
----------------------------

Sample size: considering a rate of ADR-SM possibly not over 1 % of ED patients (personal data), we targeted the enrolment of approximately 5,000 patients (in order to observe a minimum of 30 cases, alpha risk 0.05, power \>0.80).

Patient characteristics are presented as the mean and frequency with 95 % confidence intervals (CIs) using Jeffreys confidence limits for the binomial proportion. Chi-square tests for qualitative variables or Student *t* tests for quantitative variables were computed to determine if an association exists between patients admitted with ADRs and self-medication. A *p*-value of less than 0.05 was considered to be significant. In a second step, a multivariate logistic regression analysis was used to predict whether or not a patient had an ADR-SM based on significant characteristics of the patients as determined by univariate analysis. Analyses were carried out with SAS version 9.2 (SAS Institute Inc, Cary, NC, USA).

Results {#Sec12}
=======

Characteristics of the Study Population {#Sec13}
---------------------------------------

During the randomization periods, 4,661 patients were admitted to the ED. Among these, 35.1 % were not included (Fig. [1](#Fig1){ref-type="fig"}), which was most often due to inability to answer the self-medication standardized questionnaire. Table [1](#Tab1){ref-type="table"} shows the comparison of the study population with the total ED population during the study period. The demographic data appeared relatively equivalent. Nevertheless, there was a significant difference in terms of gender between the groups. Likewise, the acute severity triage score was also different, whereby level 1 was underrepresented and level 5 was overrepresented among the study patients. The 3,027 study patients were 53.5 % female (including 16 pregnant women) and had a median age of 43 years (range 18--99). The chief complaint was trauma in about one-third of the patients, with the other most frequent complaints being abdominal pain, weakness and cardiovascular diseases (Table [2](#Tab2){ref-type="table"}).Fig. 1FlowchartTable 1comparison of the study population with total emergency department (ED) population during the study periodStudy patients (%)ED population (%)^a^Age (years)*n* = 3,027*n* = 86,757 18--2927.727.9 30--3917.417.0 40--4912.914.3 50--5911.812.1 60--699.48.2 70--798.47.9 80--8910.29.7 \>892.12.8Gender*n* = 3,027*n* = 88,531*p* = 0.01 Male46.444.6 Female53.555.3CCMU^b^*n* = 2,104*n* = 58,268*p* \< 0.0001 Level 18.714.4 Level 259.459.4 Level 327.121.7 Level 44.12.7 Level 50.71.8^a^The ED population data are the administrative data obtained for the total ED population during the study period^b^The French clinical classification of emergency patients, usually used for care prioritization (9): Level 1: Clinical condition considered as stable and decision of no further procedure in the emergency room; Level 2: Level 1 and decision of further procedure in the emergency room; Level 3: Clinical condition likely to worsen; Level 4: Life-threatening risk and no decision of starting resuscitation procedures; Level 5: Level 4 and decision of starting resuscitation procedures in the emergency roomTable 2Characteristics of the study population, whether or not experiencing an ADR-SMADR-SMADR-no SM*p*-valueTotal no. of ADRsNo ADR*p*-valueStudy population*n* = 52*n* = 244(ADR-SM /ADR-noSM)*n* = 296*n* = 2,731(ADR/no ADR)*n* = 3,027Age (years)45.4 \[40.0--50.8\]67.5 \[64.9--70.0\]\<0.000163.6 \[61.1--66.1\]45.6 \[44.8--46.4\]\<0.000147.4 \[46.6--48.1\]Gender (% female)48.1 \[34.0--61.5\]57.4 \[51.1--63.5\]NS55.7 \[50.1--61.3\]45.4 \[43.6--47.3\]0.000746.5 \[44.7--48.2\]Self-medication habit (%)------77.0 \[72.2--81.8\]84.8 \[83.5--86.2\]0.000584.1 \[82.8--85.4\]Chief complaint (%) Neurologic diseases32.7 \[21.1--46.1\]11.9 \[8.3--16.4\]15.5 \[11.8--20.0\]5.9 \[5.1--6.9\]\<0.00016.9 \[6.0--7.8\] Mental illness15.4 \[7.6--26.9\]1.2 \[0.35--3.2\]3.7 \[2.0--06.3\]3.0 \[2.4--3.7\]3.1 \[2.5--3.7\] Weakness13.5 \[6.2--24.6\]16.4 \[12.2--21.4\]15.9 \[12.1--20.4\]6.5 \[5.6--7.5\]7.4 \[6.5--8.4\] Trauma11.5 \[5.0--22.2\]13.5 \[9.7--18.2\]13.2 \[9.7--17.4\]39.3 \[37.5--41.17\]36.8 \[35.1--38.5\] Cardiovascular diseases7.7 \[2.7--17. 3\]7.0 \[4.3--10.7\]7.1 \[4.6--10.4\]7.4 \[6.5--8.5\]7.4 \[6.5--8.4\] Abdominal pain5.8 \[1.7--14.6\]7.4 \[4.6--11.2\]7.1 \[4.6--10.4\]10.2 \[9.1--11.36\]9.9 \[8.9--11.0\] Endocrine and metabolic diseases5.8 \[1.7--14.6\]4.9 \[2.7--8.2\]5.1 \[3.0--08.0\]0.66 \[0.41--1.0\]1.1 \[0.8--1.5\] Musculoskeletal diseases3.9 \[0.81--11.8\]3.7 \[1.8--6.6\]^a^3.7 \[2.0--06.3\]6.1 \[5.2--7.0\]5.9 \[5.1--6.7\] Skin and soft tissues diseases1.9 \[0.21--08.6\]2.5 \[1.0--5.0\]2.4 \[1.1--04.6\]1.7 \[1.3--2.3\]1.8 \[1.4--2.3\] Respiratory diseases1.9 \[0.21--08.6\]6.2 \[3.6--9.7\]5.4 \[3.3--08.4\]5.8 \[5.0--6.8\]5.8 \[5.0--6.7\] Infections0.0 \[0\]7.0 \[4.3--10.7\]5.7 \[3.5--08.8\]4.5 \[3.7--5.3\]4.6 \[3.9--5.4\] Hepato-gastrointestinal diseases0.0 \[0\]3.7 \[1.8--6.6\]3.0 \[1.5--05.5\]2.7 \[2.1--3.3\]2.7 \[2.2--3.3\] Bleeding0.0 \[0\]12.7 \[8.97--17.3\]10.5 \[7.4--14.3\]1.5 \[1.1--2.0\]2.4 \[1.9--3.0\] Genitourinary diseases0.0 \[0\]1.2 \[0.35--3.2\]1.0 \[0.3--02.7\]1.7 \[1.3--2.3\]1.7 \[1.2--2.2\] Continuity of care0.0 \[0\]0.82 \[0.17--2.6\]0.7 \[0.1--02.2\]1.2 \[0.8--1.6\]1.1 \[0.8--1.6\] Other diseases0.0 \[0\]0.0 \[0\]0.0 \[0\]1.8 \[1.4--2.3\]1.6 \[1.2--2.1\]Medications' characteristics Average number of drugs taken5.9 \[4.8--6.9\]7.6 \[7.2--8.0\]0.00177.3 \[6.9--7.7\]3.6 \[3.5--3.8\]\<0.00014.0 \[3.8--4.1\] \>5 drugs taken (%)57.7 \[44.2--70.4\]79.1 \[73.7--83.8\]0.001175.3 \[70.2--80.0\]31.1 \[29.4--32.8\]\<0.000135.4 \[33.7--37.1\] *ATC class of drugs taken (%)* C, Cardiovascular system drugs26.9 \[16.4--40.0\]72.1 \[66.3--77.5\]0.064464.2 \[58.6--69.5\]24.8 \[23.2--26.4\]\<0.000128.6 \[27.1--30.3\] B, Blood drugs---antithrombotics and platelet aggregation inhibitors0.0 \[0\]10.7 \[7.3--15.0\]0.01198.8 \[6.0--12.4\]2.7 \[2.1--3.3\]\<0.00013.3 \[2.7--4.0\] N, Nervous system drugs (N02--analgesics excluded)67.3 \[53.9--78.9\]53.3 \[47.0--59.5\]\<0.000155.7 \[50.1--61.3\]25.6 \[24.0--27.3\]\<0.000128.6 \[27.0--30.2\] Average number of prescribed drugs3.7 \[2.8--4.8\]6.6 \[6.1--7.0\]\<0.00016.1 \[5.7--6.5\]2.3 \[2.2--2.5\]\<0.00012.7 \[2.6--2.8\] Average number of SM drugs2.2 \[1.7--2.7\]1.0 \[0.86--1.2\]\<0.00011.2 \[1.1--1.4\]1.3 \[1.2--1.3\]NS1.3 \[1.2--1.3\] At least one SM drug (%)------60.5 \[54.8--65.9\]64.0 \[62.2--65.8\]NS63.7 \[61.9--65.4\]^a^Test not performed because the conditions of application were not met*ADRs* adverse drug reactions, *ADR-SM* ADR related to self-medication, *ADR-no SM* ADR not related to self-medication, *ATC* Anatomical Therapeutic Chemical, *NS* not significant

Pharmaceutical Data {#Sec14}
-------------------

Of the patients included, 59.9 % took at least one prescribed medication, and 63.7 % self-medicated during the previous 2 weeks. Additionally, 84.1 % declared a self-medication behaviour (Table [2](#Tab2){ref-type="table"}). Of the 11,724 drugs taken by the study population, 32.5 % were in a self-medication manner, and the most frequent were analgesics (*n* = 2,184, 75 % self-medication). Among the 3,848 drugs used in self-medication, origin was most frequently a non-prescribed medication purchased over the counter (OTC) at the pharmacy (50.5 %), followed by the rest of a previous prescription (19.9 %) and the use of a conditional prescription (14.5 %). Less frequent sources of self-medication were drugs supplied by relatives (5.3 %), the use of a prescribed drug with self-modification of the dose or duration (2.1 %), drugs purchased by mail or internet (1.2 %) and other unspecified sources (6.5 %).

Frequency of ADRs Related to Self-Medication (ADR-SM) {#Sec15}
-----------------------------------------------------

Of the entire cohort, 9.8 % (296/3,027) of patients experienced an ADR that was related to self-medication in 52 cases (Fig. [1](#Fig1){ref-type="fig"}). Depending on the population considered for the denominator, the rate of ADR-SM could be expressed as 17.6 % of patients experiencing an ADR (52/296), 1.7 % of the study population (52/3,027) or 2 % of patients reporting a self-medicating behaviour (52/2,556).*ADR-SM related to prescribed drugs (self-medication behaviour):* The type of self-medication leading to an ADR was most frequently associated with prescribed drugs, as a self-modification of a prescribed treatment in 21 cases or discontinuation of treatment in 14 cases. Finally, about two-thirds of ADR-SM are subsequent to the patients' own decision on prescribed treatment.*ADR-SM related to non-prescribed drugs:* The use of non-prescribed drugs occurred in 16 cases of ADR-SM, and drug interaction with non-prescribed drugs in 1 case (so non-prescribed drugs led to a total of 17 cases of ADR-SM). The rate of ADRs related to non-prescribed drugs was 32.7 % of ADR-SM, 5.7 % of ADRs, and approximately 0.9 % among patients taking non-prescribed drugs during the previous 2 weeks (17/1,927).

Characteristics of ADR-SM in Comparison With Other ADRs {#Sec16}
-------------------------------------------------------

Bleeding was the most frequent ADR diagnosed, but for ADRs related to self-medication the diagnoses were most frequently neurologic and psychiatric. The drugs most frequently causative of ADRs were antithrombotics (class B). For ADR-SM, drugs belonging to the nervous system drugs (class N) accounted for more than half of the causative agents, of which analgesics (class N02) were significantly associated with ADR-SM. The severity of ADR-SM was lower than that of other ADRs (Table [3](#Tab3){ref-type="table"}). From the multivariate analysis, young age and ATC class N could both be considered as independent factors associated with ADR-SM (Table [4](#Tab4){ref-type="table"}).Table 3Characteristics of ADR-SM (% \[95 % CI\])ADR-SM\
*n* = 52ADR-no SM\
*n* = 244*p*-value\
(ADR-SM/ADR-noSM)Total no. of ADRs\
*n* = 296Diagnosis of ADR^a^ Neurologic diseases34.6 \[22.8--48.1\]8.6 \[5.6--12.6\]13.2 \[9.7--17.4\] Mental status change17.3 \[8.9--29.2\]2.1 \[0.79--4.4\]4.7 \[2.7--7.6\]Cardiovascular diseases9.6 \[3.8--19.8\]14.8 \[10.7--19.6\]13.9 \[10.3--18.1\] Weakness7.7 \[2.7--17.3\]4.9 \[2.7--8.2\]5.4 \[3.3--8.4\] Fall7.7 \[2.7--17.3\]7.8 \[4.9--11.7\]7.8 \[5.1--11.2\]Endocrine and metabolic diseases5.8 \[1.7--14.6\]11.9 \[8.3--16.4\]10.8 \[7.7--14.7\]Skin and soft tissues diseases5.8 \[1.7--14.6\]5.7 \[3.3--9.2\]5.7 \[3.5--8.8\]Hepato-gastrointestinal diseases5.8 \[1.7--14.6\]12.7 \[9.0--17.3\]11.5 \[8.2--15.5\] Bleeding1.9 \[0.21--8.6\]18.9 \[14.3--24.1\]15.9 \[12.1--20.4\] Infections1.9 \[0.21--8.6\]4.1 \[2.1--7.2\]3.7 \[2.0--6.3\] Others diseases1.9 \[0.21--8.6\]2.5 \[1.0--5.0\]2.4 \[1.1--4.6\] Coagulopathy02.9 \[1.3--5.6\]2.4 \[1.1--4.6\]Haematological diseases02.9 \[1.3--5.6\]2.4 \[1.1--4.6\] Respiratory diseases00.4 \[0.04--1.9\]0.3 \[0.04--1.6\]ADR severity0.032 A: Spontaneous regression34.6 \[22.8--48.1\]18.9 \[14.3--24.1\]21.6 \[17.2--26.6\] B: Regression after symptomatic treatment28.9 \[17.9--42.1\]30.3 \[24.8--36.3\]30.1 \[25.1--35.5\] C: Hospitalization with no life-threat36.5 \[24.5--50.1\]44.7 \[38.5--50.9\]43.2 \[37.7--48.9\] D: Life-threatening risk06.2 \[3.6--9.7\]5.1 \[3.0--8.0\] E: Death000ATC of causative drugs*n* = 68*n* = 404*n* = 472 C, Cardiovascular system drugs8.8 \[3.8--17.3\]27.5 \[23.3--32.0\]0.00124.8 \[21.1--28.8\] B, Blood drugs---antithrombotics and platelet aggregation inhibitors019.3 \[7.3--15.0\]\<0.000116.5 \[13.4--20.1\] N, Nervous sytem drugs (N02--analgesics excluded)55.9 \[44.0--67.2\]20.1 \[16.4--24.2\]\<0.000125.2 \[21.5--29.3\] N02--analgesics19.1 \[11.2--29.6\]5.7 \[3.7--8.3\]0.00017.6 \[5.5--10.3\]^a^Test not performed because the conditions of application were not met*ADRs* adverse drug reactions, *ADR-SM* ADRs related to self-medication, *ADR-no SM* ADRs not related to self-medication, *ATC* Anatomical Therapeutic ChemicalTable 4Characteristics explicating adverse drug reactions related to self-medicationCharacteristicsOdds ratio95 % CIAge (≥65 years vs. 18--64 years)0.120.05--0.30Gender0.750.38--1.51Nervous system drugs4.071.74--9.47Number of drugs taken (≥5 vs. 0--4)0.650.31--1.36

Discussion {#Sec17}
==========

This epidemiological study showed that self-medication could result in ADRs, representing about 1--2 % of ED patients, depending on the type of self-medication and the denominator considered. In comparison with ADRs related to a medical prescription, ADR-SM more frequently resulted in neurologic or psychiatrics side effects, and were more frequently related to nervous system drugs (ATC class N). The frequency and severity of ADRs seem to be weaker when related to self-medication. Nevertheless, these results should be carefully interpreted. The importance of the risk demonstrated here in the ED population should be weighed against the potential benefit, which has to be important enough to make the risk acceptable.

Several studies have confirmed that antithrombotic agents, especially vitamin K inhibitors, are a common cause of ADRs \[[@CR2]--[@CR4]\]. These data are confirmed in our results; however, we have not observed ADR-SM related to this class in the study population. We have observed that the most common class associated with ADR-SM was psycholeptic and analgesic drugs. The increasing consumption of analgesic self-medication highlights the need for information and prevention regarding the risks of OTC medications \[[@CR15]\], particularly as patients commonly underrate the risks of ADR-SM \[[@CR16]\]. Moreover, the high frequency of ADR-SM associated with self-modification or self-discontinuation of treatment advocates strongly for patient education, especially for the use of psycholeptic and antiepileptic drugs. Tracks for the analysis of ADR-SM were proposed 2 decades ago to understand how they arise \[[@CR17]\], whereby the most commonly explored are factors dependent on doctors, healthcare professionals and institutions. On the other hand, factors that appear linked to the patient and to the doctor-patient relationship are lesser studied. As a consequence, the patients' therapeutic behaviours and self-medication with non-prescribed drugs must be examined to explore actual causes of ADRs. Indeed, the individual's assessment of illness and their subsequent response to it are not so spontaneous, as these result from learning (not only with professionals) that is based on the representation of illness and medications \[[@CR18]\].

This sociopsychological approach considers the patient as greater in importance than the drug or the professional. Therefore, the definition of self-medication should not be restricted to OTC drugs. In a national French report \[[@CR19]\], self-medication was recognized as a behaviour rather than as a class of medications (specifically OTC, as it is recognized in the UK). This approach allows for the inclusion of all therapeutic choices decided by the patient in the definition of self-medication and self-medicating behaviour. However, scientific data regarding self-medication are, to date, rare in the medical literature, and they mostly concern OTC drugs and focus on pharmaceutical aspects of self-medication \[[@CR20], [@CR21]\]. Moreover, data that are available tend to be quantitative consumption data issued from industry and pharmacist surveys regarding only OTC medicines \[ISM Health, AESGP (Association Européenne des Spécialités Pharamaceutiques Grand Public) for the European self-medication industry \[[@CR19]\]\] or they are declarative data from patients themselves revealed by some opinion surveys. In France, the use of drugs available without medical order is lower than in other countries, being about 8 % of revenue and 17 % of sale units \[[@CR19]\]. Additionally, the frequency of declared self-medication is about 80 % among people interviewed by opinion survey promoted by pharmaceutical manufacturers \[[@CR22]\], which is in line with our results. Several risks are related to self-medication, of which ADRs are a part. Self-medication is also associated with diagnostic risks, because the treatment of symptoms could be delayed before visiting a physician or the clinical setting could be modified enough to lead the physician to a medical error. Other risks should also be considered in the overall management of self-medication, such as exacerbation of psychiatric diseases \[[@CR23], [@CR24]\] and addiction to drugs \[[@CR25]\]. Strategies to control and to minimize the risk of self-medication should involve monitoring systems, the promotion of education and information, and a partnership between patients, physicians and pharmacists \[[@CR26], [@CR27]\].

The context and objectives of this study have generated some bias that requires discussion. Because of the focus of this study, the self-medication behaviours are explored by self-report, restricting those enrolled to patients able to answer the standardized questionnaire. Therefore, the sample of included patients could not exactly represent the entire ED population, particularly along the lines of the severity of illness. Moreover, the collection of declarative data could lead to recall and reporting bias. The known discrepancies in self-medication access, depending on local rules and on the financial ability of patients to pay for their drugs, could also have influenced our results. Despite these recognized limits, the overall quality of this survey renders our results strong enough to be considered as quantitative of the frequency of ADR-SM in patients admitted to the ED.

Conclusion {#Sec18}
==========

Self-medication could lead to the alteration of individual's health status in about 1 % of the population reporting self-medication behaviours, as shown here in the ED population. This first result of frequency and severity of ADRs related to self-medication should lead to further studies beyond the ED population. The misuse of self-medication in the general population and its potential impact on the occurrence of ADRs has to be further explored. Before considering self-medication as a safe and economic method of care, the reality of the risk related to self-medication should be taken into account by healthcare professionals and institutions. In addition, prevention strategies should include all aspects of self-medication (including self-use of prescribed drugs), which must be re-configured to make self-medication a valuable way of care involving all concerned, including patients and healthcare professionals.
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